Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3359134 | 0.98 | — | — | |
| SCHEMBL20436909 | 0.98 | — | — | |
| SCHEMBL3058658 | 0.98 | — | — | |
| SCHEMBL22901314 | 0.98 | — | — | |
| Methane SCHEMBL27613756 | 0.95 | LMNA (0.41) | LMNACYP2C9GPR119 | |
| SCHEMBL16903314 | 0.86 | LMNA (0.41) | LMNACYP2C9 | |
| SCHEMBL24477583 | 0.78 | GPR119 (0.36) | LMNACYP2C9GPR119 | |
| SCHEMBL16903316 | 0.78 | GPR119 (0.36) | LMNACYP2C9GPR119 | |
| SCHEMBL28451441 | 0.73 | — | — | |
| SCHEMBL10233235 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-02-15 | — | — | US | disclosed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2016055901-A1 | SUBSTITUTED AMIDE COMPOUNDS | PFIZER INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102074-A1 | SUBSTITUTED AMIDE COMPOUNDS | PFIZER INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160058768-A1 | SUBSTITUTED AMIDE COMPOUNDS | PFIZER (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2986599-A1 | N-PIPERIDIN-3-YLBENZAMIDE DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | Pfizer Inc. (US) | 2016-02-24 | — | — | EP | disclosed |
| US-9227956-B2 | Substituted amide compounds | PFIZER INC. (US) | 2016-01-05 | — | — | US | disclosed |
| EP-0992496-A1 | Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | Pfizer Products Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-2000017165-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000017166-A1 | 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0987251-A1 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | Pfizer Products Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5965553-A | Squalene synthetase inhibitors | PFIZER INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5807834-A | ANTICHOLESTEROL AGENTS | PFIZER INC. (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0814080-A1 | Squalene synthetase inhibitors | PFIZER INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997048701-A1 | 4,1-BENZOXAZEPINES OR 4,1-BENZOTHIAZEPINES AND THEIR USE AS SQUALENE SYNTHETASE INHIBITORS | PFIZER INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| EP-0782451-A1 | COMBINATION OF A CHOLESTEROL ABSORPTION INHIBITOR AND A CHOLESTEROL SYNTHESIS INHIBITOR | PFIZER INC. (US) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009827-A2 | COMBINATION OF A CHOLESTEROL ABSORPTION INHIBITOR AND A CHOLESTEROL SYNTHESIS INHIBITOR | PFIZER INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | LMNA 705/4885CYP2C9 1631/4885GPR119 562/4885 |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | LMNA 642/4885CYP2C9 2216/4885GPR119 919/4885 |
| US-20160102074-A1 | SUBSTITUTED AMIDE COMPOUNDS | CETP, APOB, LCAT | LMNA 1068/4885CYP2C9 936/4885GPR119 177/4885 |
| US-20160058768-A1 | SUBSTITUTED AMIDE COMPOUNDS | CETP, APOB, LCAT | LMNA 1068/4885CYP2C9 936/4885GPR119 177/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | LMNA 642/4885CYP2C9 2216/4885GPR119 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.